Competitor Analysis: Insulin

• 1. Insulin Market

• 2. Inhaled Insulins

• 3. Nasal and Transdermal insulin

• 4. Oral Insulins

• 5. Engineered and Follow-up Insulins

Special Company Pipelines

• 1.- Emisphere Technologies

• 2005 worldwide market of insulin and analogs of > 7.2 bln;
• major insulin market players are Novo Nordisk, Eli Lilly and Sanofi-Aventis;
• ongoing conversion from rhu insulin to insulin analogs;
• portfolios of short- and long-acting insulin analogs

• Gene and target discovery based on population genetics
• Advanced clinical phase projects by using in-licensed “old drugs” against “new targets”;
• Three clinical stage projects and two IND candidates for 2006;
• Ongoing collaboration with Roche on PDE4 inhibitors for vascular diseases

• Core competence in toll-like receptors (TLR) and regulatory T-cells
• Spin-off from Trinity College, Dublin in 2003;
• Collaboration with Wyeth on TLR-targeted drug discovery and on new targets of the TLR pathway;
• Potential phase I start in 2006 of OPN-101 (immunomodulatory filamentous hemaglutinin A)

• First product approved in Ecuador ;
• Most advanced Western technology from Emisphere Technologies;
• Emisphere started phase II study with 3-months treatment;
• Technologies with nine projects include buccal sprays, enteric coated tablets and gel capsules
  

• Substantial growth of insulin need expected (more diabetics and new delivery systems);
• Transgenic plant insulin approaching clinical testing in 2006;
• Follow-up insulins from India and other territories with cost-efficient production;
• Engineered insulin with longer half-life in very early stages
  

• Broad-based oral drug delivery technology platform (eligen technology);
• Use of synthetic chemical carrier compounds enable macromolecules to penetrate membranes;
• Major alliance with Novartis on oral calcitonin, human growth hormone and PTH;
• Most advanced project of oral heparin in phase III
• Oral calcitonin and oral insulin in phase II evaluation